» Articles » PMID: 27571885

Chemotherapy for Adult Low-grade Gliomas: Clinical Outcomes by Molecular Subtype in a Phase II Study of Adjuvant Temozolomide

Abstract

Background: Optimal adjuvant management of adult low-grade gliomas is controversial. Recently described tumor classification based on molecular subtype has the potential to individualize adjuvant therapy but has not yet been evaluated as part of a prospective trial.

Methods: Patients aged 18 or older with newly diagnosed World Health Organization grade II low-grade gliomas and gross residual disease after surgical resection were enrolled in the study. Patients received monthly cycles of temozolomide for up to 1 year or until disease progression. For patients with available tissue, molecular subtype was assessed based upon 1p/19q codeletion and isocitrate dehydrogenase-1 R132H mutation status. The primary outcome was radiographic response rate; secondary outcomes included progression-free survival (PFS) and overall survival (OS).

Results: One hundred twenty patients were enrolled with median follow-up of 7.5 years. Overall response rate was 6%, with median PFS and OS of 4.2 and 9.7 years, respectively. Molecular subtype was associated with rate of disease progression during treatment (P<.001), PFS (P=.007), and OS (P<.001). Patients with 1p/19q codeletion demonstrated a 0% risk of progression during treatment. In an exploratory analysis, pretreatment lesion volume was associated with both PFS (P<.001) and OS (P<.001).

Conclusions: While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy. Patients with 1p/19q codeletion are potential candidates for omission of adjuvant radiotherapy, but further work is needed to directly compare chemotherapy with combined modality therapy.

Citing Articles

Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database.

Zhou Y, Jia P, Fang Y, Zhu W, Gong Y, Fan T Front Pharmacol. 2024; 15:1437436.

PMID: 39246656 PMC: 11377320. DOI: 10.3389/fphar.2024.1437436.


Longitudinal assessment of quality of life, neurocognition, and psychopathology in patients with low-grade glioma on first-line temozolomide: A feasibility study.

Darlix A, Monnier M, Castan F, Coutant L, Fabbro M, Denis-Chammas E Neurooncol Adv. 2024; 6(1):vdae084.

PMID: 38946878 PMC: 11212068. DOI: 10.1093/noajnl/vdae084.


IDH inhibition in gliomas: from preclinical models to clinical trials.

Ruda R, Horbinski C, van den Bent M, Preusser M, Soffietti R Nat Rev Neurol. 2024; 20(7):395-407.

PMID: 38760442 DOI: 10.1038/s41582-024-00967-7.


Brain Plasticity Profiling as a Key Support to Therapeutic Decision-Making in Low-Grade Glioma Oncological Strategies.

Ng S, Duffau H Cancers (Basel). 2023; 15(14).

PMID: 37509359 PMC: 10378506. DOI: 10.3390/cancers15143698.


Benign Glioma.

Wu P, Filley A, Miller M, Bruce J Adv Exp Med Biol. 2023; 1405:31-71.

PMID: 37452934 DOI: 10.1007/978-3-031-23705-8_2.


References
1.
Klein M, Heimans J, Aaronson N, VAN DER Ploeg H, Grit J, Muller M . Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002; 360(9343):1361-8. DOI: 10.1016/s0140-6736(02)11398-5. View

2.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

3.
McGirt M, Chaichana K, Attenello F, Weingart J, Than K, Burger P . Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008; 63(4):700-7. DOI: 10.1227/01.NEU.0000325729.41085.73. View

4.
Donahue B . Short- and long-term complications of radiation therapy for pediatric brain tumors. Pediatr Neurosurg. 1992; 18(4):207-17. DOI: 10.1159/000120664. View

5.
Mason W, Krol G, DeAngelis L . Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996; 46(1):203-7. DOI: 10.1212/wnl.46.1.203. View